Vascular Endothelial Growth Factor Receptor-3
"Vascular Endothelial Growth Factor Receptor-3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A vascular endothelial cell growth factor receptor whose expression is restricted primarily to adult lymphatic endothelium. VEGFR-3 preferentially binds the vascular endothelial growth factor C and vascular endothelial growth factor D and may be involved in the control of lymphangiogenesis.
Descriptor ID |
D040321
|
MeSH Number(s) |
D08.811.913.696.620.682.725.400.950.300 D12.776.543.750.630.750.300 D12.776.543.750.750.400.910.300
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Vascular Endothelial Growth Factor Receptor-3".
Below are MeSH descriptors whose meaning is more specific than "Vascular Endothelial Growth Factor Receptor-3".
This graph shows the total number of publications written about "Vascular Endothelial Growth Factor Receptor-3" by people in this website by year, and whether "Vascular Endothelial Growth Factor Receptor-3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 0 | 1 | 1 |
2018 | 1 | 0 | 1 |
2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vascular Endothelial Growth Factor Receptor-3" by people in Profiles.
-
Liu S, Knochelmann HM, Lomeli SH, Hong A, Richardson M, Yang Z, Lim RJ, Wang Y, Dumitras C, Krysan K, Timmers C, Romeo MJ, Krieg C, O'Quinn EC, Horton JD, Dubinett SM, Paulos CM, Neskey DM, Lo RS. Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma. Cell Rep Med. 2021 10 19; 2(10):100411.
-
Crona DJ, Skol AD, Leppänen VM, Glubb DM, Etheridge AS, Hilliard E, Peña CE, Peterson YK, Klauber-DeMore N, Alitalo KK, Innocenti F. Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib. Cancer Res. 2019 01 01; 79(1):231-241.
-
Mercer AA, Wise LM, Scagliarini A, McInnes CJ, Büttner M, Rziha HJ, McCaughan CA, Fleming SB, Ueda N, Nettleton PF. Vascular endothelial growth factors encoded by Orf virus show surprising sequence variation but have a conserved, functionally relevant structure. J Gen Virol. 2002 Nov; 83(Pt 11):2845-2855.